source
- Rezera files for IPO to back NLRP3 work in peripheral artery diseaseRezera, the biotech that rebranded from NodThera earlier this year, has entered the queue for an initial public offering to bolster its decade-long NLRP3 efforts. The biotech submitted its pitch We…Endpoints · 40m ago↗ source
- China biotech RiboX reveals first data of circular RNA therapies in peopleBiotech investors and pharma companies have poured billions into three Boston-region startups competing to develop a next-generation version of mRNA technology that could make for more durable and…Endpoints · 1h ago↗ source
- FDA approves Hibsago, first antisense therapy for chronic hepatitis BThe U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for chronic hepatitis B virus infection in certain adults without…